Clinical trial · no report yet · Phase 3
Krascendo 1
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT06497556 ↗
- Active not recruiting
- Hoffmann-La Roche
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
- Interventions
- Divarasib; Sotorasib; Adagrasib
- Arms
- Divarasib · Experimental
- KRAS G12C inhibitor · Active comparator
- Enrollment
- 338
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche with Chugai Pharmaceutical
- Start
- Sep 23, 2024
- Primary completion
- May 19, 2026
- Results posted
- No
- Registry record
- NCT06497556 · updated Sep 16, 2026